Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.

Key facts

Study ID

NCT02210780

Run by

Regeneron Pharmaceuticals

People needed

194

Starts

2014-08-05

Expected to finish

2015-09-15

Last updated by the study team

2020-05-07

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Fort Smith, Arkansas, United States
• Study site — Long Beach, California, United States
• Study site — Los Angeles, California, United States
• Study site — Mission Viejo, California, United States
• Study site — Rolling Hills Estates, California, United States
• Study site — San Diego, California, United States
• Study site — Santa Monica, California, United States
• Study site — Denver, Colorado, United States
• Study site — Jacksonville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Macon, Georgia, United States
• Study site — Chicago, Illinois, United States
• Study site — Maywood, Illinois, United States
• Study site — West Dundee, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Plainfield, Indiana, United States
• Study site — Overland Park, Kansas, United States
• Study site — Boston, Massachusetts, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Troy, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Hackensack, New Jersey, United States
• Study site — Albuquerque, New Mexico, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.